There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on OpGen Inc (NASDAQ: OPGN), Summit Therapeutics (NASDAQ: SMMT) and Can-Fite BioPharma (NYSE: CANF) with bullish sentiments.
OpGen Inc (NASDAQ: OPGN)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on OpGen Inc (NASDAQ: OPGN) yesterday and set a price target of $9. The company’s shares closed yesterday at $2.30, close to its 52-week low of $1.62.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.8% and a 40.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
OpGen Inc has an analyst consensus of Moderate Buy, with a price target consensus of $9.
See today’s analyst top recommended stocks >>
Summit Therapeutics (NASDAQ: SMMT)
In a report released yesterday, Debjit Chattopadhyay from H.C. Wainwright maintained a Buy rating on Summit Therapeutics (NASDAQ: SMMT), with a price target of $20. The company’s shares closed yesterday at $12.64.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 2.2% and a 48.4% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Summit Therapeutics is Strong Buy and the average price target is $28, representing a 121.5% upside.
In a report issued on June 6, Canaccord Genuity also maintained a Buy rating on the stock with a $28 price target.
Can-Fite BioPharma (NYSE: CANF)
H.C. Wainwright analyst Jason Kolbert initiated coverage with a Buy rating on Can-Fite BioPharma (NYSE: CANF) yesterday. The company’s shares closed yesterday at $1.34, close to its 52-week low of $1.24.
According to TipRanks.com, Kolbert is a 1-star analyst with an average return of -1.4% and a 39.3% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Anavex Life Sciences, Cytori Therap, and Mesoblast Ltd.
Can-Fite BioPharma has an analyst consensus of Moderate Buy.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
